Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Holdings Decreased by Kintegral Advisory LLC

Kintegral Advisory LLC trimmed its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 32.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,648 shares of the pharmaceutical company's stock after selling 2,280 shares during the period. Kintegral Advisory LLC's holdings in Vertex Pharmaceuticals were worth $2,253,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Capital World Investors boosted its position in Vertex Pharmaceuticals by 5.7% during the fourth quarter. Capital World Investors now owns 28,325,695 shares of the pharmaceutical company's stock worth $11,406,667,000 after acquiring an additional 1,514,993 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Vertex Pharmaceuticals by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 23,258,288 shares of the pharmaceutical company's stock worth $9,366,113,000 after purchasing an additional 98,654 shares during the last quarter. Capital Research Global Investors grew its position in shares of Vertex Pharmaceuticals by 15.8% in the fourth quarter. Capital Research Global Investors now owns 10,428,951 shares of the pharmaceutical company's stock valued at $4,199,713,000 after purchasing an additional 1,426,746 shares during the period. Wellington Management Group LLP increased its stake in Vertex Pharmaceuticals by 23.3% in the fourth quarter. Wellington Management Group LLP now owns 5,916,084 shares of the pharmaceutical company's stock valued at $2,382,407,000 after purchasing an additional 1,117,214 shares during the last quarter. Finally, Loomis Sayles & Co. L P lifted its position in Vertex Pharmaceuticals by 23.0% during the fourth quarter. Loomis Sayles & Co. L P now owns 3,772,789 shares of the pharmaceutical company's stock worth $1,519,302,000 after buying an additional 704,575 shares during the period. 90.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have commented on VRTX. Cantor Fitzgerald restated an "overweight" rating and issued a $535.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Wolfe Research downgraded shares of Vertex Pharmaceuticals from an "outperform" rating to a "peer perform" rating in a report on Wednesday, May 7th. Leerink Partners reaffirmed a "market perform" rating and set a $503.00 price target (down previously from $550.00) on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. JPMorgan Chase & Co. lifted their price target on shares of Vertex Pharmaceuticals from $512.00 to $515.00 and gave the company an "overweight" rating in a report on Tuesday, May 6th. Finally, HC Wainwright restated a "buy" rating and set a $550.00 price objective on shares of Vertex Pharmaceuticals in a report on Monday, June 23rd. Fourteen research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $511.62.

Vertex Pharmaceuticals Stock Down 0.5%

Vertex Pharmaceuticals stock traded down $2.40 during midday trading on Friday, hitting $454.64. The stock had a trading volume of 763,957 shares, compared to its average volume of 1,418,533. The company has a current ratio of 2.65, a quick ratio of 2.29 and a debt-to-equity ratio of 0.01. The business has a fifty day moving average price of $451.62 and a 200 day moving average price of $458.44. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The stock has a market cap of $116.75 billion, a P/E ratio of -115.98 and a beta of 0.41.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 8.91% and a negative return on equity of 3.36%. The firm had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.85 billion. During the same period in the prior year, the company posted $4.76 earnings per share. The business's revenue was up 2.6% on a year-over-year basis. Research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.